White House Coronavirus Task Force lead member Anthony Fauci in an interview with STAT on Monday said he was disappointed with the way Moderna Inc. MRNA 4.48% chose to publish data from phase 1 clinical trial of its novel coronavirus (COVID-19) vaccine.
“I didn’t like that,” the National Institute of Allergy and Infectious Diseases director told STAT.
Fauci said the vaccine maker should have waited to get the complete
data from the first phase of the study and publish it in a “reputable
journal.”
“But the company, when they looked at the data, as all companies do,
they said, wow, this is exciting. Let’s put out a press release,” he
added.
According to Fauci, the complete data is “quite similar” to the
snippet Moderna published in the press release, and gives a reason to be
“cautiously optimistic.”
“The initial data look very promising from the neutralizing antibody standpoint,” the NIAID director told STAT.
On other vaccines under development, Fauci said that Pfizer Inc.’s PFE 1.63%
COVID-19 vaccine is very similar to that of Moderna’s candidate, and
there’s no reason to believe that the results of its candidate will be
any different.
“It’s an mRNA vaccine. I’m sure that Pfizer is going to get results that are as good as the Moderna vaccine,” he told STAT.
https://www.benzinga.com/news/20/06/16156922/fauci-reiterates-moderna-vaccine-data-is-cautiously-optimistic-expects-pfizers-results-to-be-the-sam
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.